With strong hedge fund interest and a low price-to-earnings ratio, Pfizer Inc. (NYSE:PFE) secures a place on our list of the ...

Pfizer beats Q2 estimates with $14.7B revenue and $0.78 EPS. Management showed extreme confidence by raising full-year EPS ...

We recently published 10 Stocks Jim Cramer Discussed As He Questioned Official Data. Pfizer Inc. (NYSE:PFE) is one of the ...

Pfizer (PFE) recently announced positive topline results from the Phase 3 EV-303 clinical trial, showcasing promising ...

Pfizer Inc. just made headlines by acquiring a promising biotech firm. The strategic move aims to enhance Pfizer's portfolio ...

Pfizer's stock rose 8.03%, despite bearish technicals and mixed analyst ratings. Technical indicators signal a bearish ...

Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...

Pfizer's strong EPS surprise streak and positive earnings revisions are encouraging, but patent cliff risks remain a major ...

Pfizer's Phase 3 trial of inclacumab in sickle cell disease misses its main goal but shows safety, with further updates on other drugs planned.

Pfizer (NYSE: PFE) was a hot stock during the pandemic, but it has been crashing in recent years. The company's COVID vaccine ...

Drugmaker Pfizer ($PFE) recently shared disappointing news about its experimental drug for sickle cell disease, inclacumab. In a late-stage ...

Pfizer's COVID-19 vaccine for children under five may lose FDA authorization, leading to potential supply shortages. Modern ...